Journal · Drug therapy and pharmacology · Updated 15 November 2026
Drugs
Read articles from Drugs on DeepDyve. No hospital or university library needed.
Drugs has published reviews of drug therapy and pharmacology since 1971, from profiles of newly approved medicines to overviews of how specific conditions are treated. A DeepDyve subscription lets you read it in full, alongside millions of articles from other journals licensed from publishers including Springer Nature.
Then $59 a month or $499 a year. A credit card is required; cancel during the trial and you won’t be charged. You read articles online; PDFs are sold separately. Personal plans aren’t for business use: reading for work? See Enterprise.
Drugs at a glance
- Full title
- Drugs
- Abbreviation (NLM)
- Drugs
- Publisher
- Springer Nature
- Print ISSN
- 0012-6667
- Online ISSN (eISSN)
- 1179-1950
- First published
- 1971
- Subjects
- Drug Therapy, Pharmacology
- Access model
- Hybrid: subscription, with an open access option
- On DeepDyve
- Research articles; availability varies by article
Ways to access Drugs
42% of the articles Drugs published from January 1 to November 13, 2026 are open access and free to read. For the rest, look for the authors’ manuscript, check a library, or read them on DeepDyve.
- Open access articles. 42% of Drugs articles published from January 1 to November 13, 2026 carry a Creative Commons license, per Crossref, and are free to read. They’re marked “Open access” below.
- The authors’ accepted manuscript. For subscription articles, Springer Nature lets authors post their accepted manuscript on their own website as soon as it’s accepted, and in a repository such as PubMed Central 12 months after publication.
- Ask the authors. Authors can also share a free, read-only link to their published article through Springer Nature’s SharedIt, so it’s worth asking the authors directly.
- NIH-funded research. For papers accepted on or after July 1, 2025, the US National Institutes of Health requires the accepted manuscript in PubMed Central, free with no embargo from the official publication date.
- A library. Your university, hospital or public library may subscribe to Drugs. Check its journal list and whether it offers remote access.
- DeepDyve. Read Drugs articles online for $59 a month or $499 a year after a free first month. Articles marked LitStream below are in DeepDyve’s LitStream collection, which a subscription lets you read online. PDFs are sold separately, and availability varies by article.
Sources: Springer Nature self-archiving policy; NIH Public Access Policy; open access share from Crossref license data.
Impact factor and metrics
Drugs’ 2025 Journal Impact Factor is 14.7, and its 5-year Impact Factor is 14.4.
14.7
Journal Impact Factor (2025)
14.4
5-year Impact Factor (2025)
8 days
Median time to first decision
2M
Downloads (2025)
Source: journal metrics on the Drugs homepage (Springer Nature), checked November 15, 2026. Impact Factor from Clarivate Journal Citation Reports.
Recent Drugs research worth reading
Published March to October 2026. Summaries describe what the authors report.
-
Plozasiran: First Approval
The authors trace the development of plozasiran, an RNA interference drug that lowers the liver’s production of ApoC3, up to its first approval in the USA on November 18, 2025, alongside diet, to reduce triglycerides in adults with familial chylomicronemia syndrome.
Syed · Drugs, published online March 6, 2026 · DOI 10.1007/s40265-026-02293-2
-
Orforglipron: First Approval
The authors trace the development of orforglipron, a GLP-1 drug taken by mouth, to its first approval in the USA in April 2026, alongside diet and exercise, for long-term weight management in adults with obesity or with overweight and a weight-related condition.
Drugs, October 2026 · DOI 10.1007/s40265-026-02363-5
-
Incretin-Based Anti-obesity Medications in Polycystic Ovary Syndrome: The Evidence Map
Mapping the evidence for liraglutide, semaglutide and tirzepatide in polycystic ovary syndrome, the authors report that liraglutide has the most PCOS-specific data, semaglutide data are sparse and tirzepatide has none, and call for PCOS-specific trials.
Jensterle et al. · Drugs, published online May 9, 2026 · DOI 10.1007/s40265-026-02325-x
-
GOLD 2026: Transforming COPD Management with Early Intervention, Multi-dimensional Assessment, and Personalized Care
The authors review the 2026 GOLD report on COPD, which stresses early diagnosis and personalized care, uses blood eosinophil counts to guide inhaled steroids, and adds dupilumab and mepolizumab for patients with eosinophilic COPD who are prone to flare-ups.
Drugs, May 2026 · DOI 10.1007/s40265-026-02303-3
-
Metabolic Dysfunction-Associated Steatohepatitis (MASH)-Cirrhosis Clinical Trials: Lessons Learned and Future Directions
Looking at trial design for cirrhosis caused by metabolic dysfunction-associated steatohepatitis (MASH), the authors propose that future drug trials enroll high-risk patients, plan 3 to 5 years of follow-up and use noninvasive criteria to select patients.
Drugs, May 2026 · DOI 10.1007/s40265-026-02301-5
Related journals
Questions about Drugs
How can I read Drugs articles without a subscription?
42% of Drugs articles published from January 1 to November 13, 2026 are open access and free to read. For subscription articles, Springer Nature lets authors post their accepted manuscript on their own website as soon as it’s accepted, and in a repository such as PubMed Central 12 months after publication. Your library may also subscribe. DeepDyve lets you read Drugs articles online for $59 a month or $499 a year after a free first month.
What is the abbreviation for Drugs?
Drugs isn’t abbreviated: its NLM (PubMed) abbreviation is simply Drugs.
What is the ISSN of Drugs?
The print ISSN is 0012-6667 and the online ISSN is 1179-1950.
What is the impact factor of Drugs?
Drugs’ Journal Impact Factor is 14.7 (2025), and its 5-year Impact Factor is 14.4, according to Springer Nature’s published metrics.
Is Drugs open access?
Drugs is a hybrid journal: most articles are published under the subscription model, and authors can choose to publish open access. From January 1 to November 13, 2026, 58 of 138 Drugs articles (42%) carry a Creative Commons license, per Crossref.
Drugs articles on DeepDyve are licensed from Springer Nature. Journal facts as of 15 November 2026.
Start reading Drugs today
One month free, then less than $2 a day. Drugs, plus millions of articles from thousands of journals.







